


## EPZ011989

<b>Cat. No.:</b>	HY-16986		
<b>CAS No.:</b>	1598383-40-4		
<b>Molecular Formula:</b>	C <sub>35</sub> H <sub>51</sub> N <sub>5</sub> O <sub>4</sub>		
<b>Molecular Weight:</b>	605.81		
<b>Target:</b>	Histone Methyltransferase		
<b>Pathway:</b>	Epigenetics		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (165.07 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		1.6507 mL	8.2534 mL	16.5068 mL
<b>5 mM</b>			0.3301 mL	1.6507 mL	3.3014 mL	
		<b>10 mM</b>		0.1651 mL	0.8253 mL	1.6507 mL
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (4.13 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.13 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (4.13 mM); Clear solution</li> </ol>					

### BIOLOGICAL ACTIVITY

<b>Description</b>	EPZ011989 is a potent and orally active Zeste Homolog 2 (EZH2) inhibitor with metabolic stability. EPZ011989 has inhibitory inhibition for EZH2 with a K <sub>i</sub> value of <3 nM. EPZ011989 shows robust methyl mark inhibition and anti-tumor activity. EPZ011989 can be used for the research of various cancers <sup>[1]</sup> . EPZ011989 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing Azide groups.
<b>IC<sub>50</sub> &amp; Target</b>	EZH2

**In Vitro**

EPZ011989 inhibits mutant and wild-type EZH2 with an  $K_i$  value of  $<3$  nM<sup>[1]</sup>.  
 ?EPZ011989 reduces cellular H3K27 methylation with an  $IC_{50}$  value of 94 nM<sup>[1]</sup>.  
 ?EPZ011989 (0-10  $\mu$ M; 11 days) has anti-proliferation effect in WSU-DLCL2 cells<sup>[1]</sup>.  
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.  
 Cell Proliferation Assay<sup>[1]</sup>

Cell Line:	WSU-DLCL2 cells
Concentration:	0-10 $\mu$ M
Incubation Time:	11 days
Result:	Demonstrated an average lowest cytotoxic concentration (LCC) in WSU-DLCL2 cells of 208 nM.

**In Vivo**

EPZ011989 (oral; 30-1000 mg/kg; single or bid; for 7 days or 21 days) can elicit robust methyl mark inhibition and antitumor activity<sup>[1]</sup>.  
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SCID mice <sup>[1]</sup>
Dosage:	125, 250, 500, and 1000 mg/kg
Administration:	Oral; single, twice-daily (BID) for 7 days or twice-daily (BID) for 21 days
Result:	Provided coverage over the LCC for 24 h (1000 mg/kg), while the 250 and 500 mg/kg doses provided coverage over this value for approximately 8 h. Observed complete ablation of the methyl mark by the end of day 7. Showed robust tumor growth inhibition, methyl mark reduction and extended total and free plasma exposure time.

Animal Model:	Rat <sup>[1]</sup>																												
Dosage:	30, 100, and 300 mg/kg																												
Administration:	Oral, single																												
Result:	<table border="1"> <thead> <tr> <th>dose (mg/kg)</th> <th>route</th> <th><math>t_{1/2}</math> (h)</th> <th><math>t_{max}</math> (h)</th> <th><math>C_{max}</math> (ng/mL)</th> <th><math>AUC_{inf}</math> (h*ng/mL)</th> <th>time above LCC (h)</th> </tr> </thead> <tbody> <tr> <td>30</td> <td>p.o.</td> <td>4.7</td> <td>2</td> <td>240</td> <td>970</td> <td>4</td> </tr> <tr> <td>100</td> <td>p.o.</td> <td>3.9</td> <td>2.7</td> <td>1600</td> <td>5600</td> <td>8</td> </tr> <tr> <td>300</td> <td>p.o.</td> <td>3.7</td> <td>2.7</td> <td>2900</td> <td>10000</td> <td>10</td> </tr> </tbody> </table>	dose (mg/kg)	route	$t_{1/2}$ (h)	$t_{max}$ (h)	$C_{max}$ (ng/mL)	$AUC_{inf}$ (h*ng/mL)	time above LCC (h)	30	p.o.	4.7	2	240	970	4	100	p.o.	3.9	2.7	1600	5600	8	300	p.o.	3.7	2.7	2900	10000	10
dose (mg/kg)	route	$t_{1/2}$ (h)	$t_{max}$ (h)	$C_{max}$ (ng/mL)	$AUC_{inf}$ (h*ng/mL)	time above LCC (h)																							
30	p.o.	4.7	2	240	970	4																							
100	p.o.	3.9	2.7	1600	5600	8																							
300	p.o.	3.7	2.7	2900	10000	10																							

**CUSTOMER VALIDATION**

- 
- Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2961-2966.
  - J Immunother Cancer. 2021 May;9(5):e001335.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. Campbell JE, et al. EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity. ACS Med Chem Lett. 2015 Mar 4;6(5):491-495.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA